Clark’s stock continued for a second day and raised the prospect that an activist investor could surface and try to block its merger-of-equals deal with Tylenol maker Kenvue.

The recent publicity could allow the company to get a good deal on Kenvue, which makes Tylenol, Band-Aids, and other ...

Dow Jones Top Financial Services Headlines at 11 AM ET: Bank of America's First Investor Day Since 2011 Is Coming. Why the CEO Is on the Hot Seat. | Financial ... Bank of America's First Investor Day ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

"Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn" was originally created and published by Pharmaceutical ...

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

In this piece, we will look at the stocks Jim Cramer discussed.

Kimberly-Clark, the maker of Huggies, said Monday it will acquire Kenvue, Tylenol’s parent, in a cash-and-stock transaction valued at nearly $50 billion. The companies said the combined portfolio will ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a huge consumer ...

Asian shares are trading mixed after overseas markets got a big lift from optimism over AI technology. Shares rose in Hong Kong on Tuesday, while slipping in Tokyo, Sydney and Seoul. On Wall ...